Kimberly Bambach, Ms. Wolf's predecessor, continues with Tivic as advisor focused on strategic transactions and special projects Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions and other special projects. "Lisa has served as a senior member of Tivic's finance team for over two

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions aim to strengthen the company's financial foundation and bring growth and M&A expertise to the team. Ms. Bambach brings over 30 years of financial leadership experience in both public and private companies across industries. Her background includes financial leadership in medical and retail markets, manufacturing, wholesale distrib

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q2 2024 financial results and a corporate update via pre-recorded conference call and webcast on Wednesday, August 14 at 1:30 PM PT / 4:30 PM ET. Current shareholders, interested individuals and future investors are encouraged to join the webcast to hear the company executives provide a corporate update that will highlight the importance of Tivic's vagus nerve research program and its market potential. The company invites questions to be submitted to [email protected] by August 11, 2024. Teleconference Details:

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q1 2024 financial results via pre-recorded conference call and webcast on Wednesday, May 15th at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 464810 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/50489 About Tivic Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic's patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures

Tivic Health® Systems, Inc. ("Tivic Health") (NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its year-end financial results for 2023 via pre-recorded conference call and webcast on Monday, March 25, 2024 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 434944 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/50026 About Tivic Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic's patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus

71% Gross Profit Increase; 30% Decrease in Operating Expenses Tivic Health® Systems, Inc. (("Tivic", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the third quarter 2023 ended September 30, 2023 ("Q3 2023"). Third Quarter 2023 Financial Highlights Revenue for Q3 2023 was $282 thousand, compared to $161 thousand for Q2 2023 and $477 thousand in Q3 2022. Gross profit was $108 thousand, compared to $63 thousand in Q3 2022, an increase of 71%. Gross Margin of 38% in Q3 2023, compared to 13% in Q3 2022. Total operating expenses for Q3 2023 was $1.9 million, compared to $2.6 million for Q3 2022, a d

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the third quarter 2023 via pre-recorded conference call and webcast on Tuesday, November 14th, 2023 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 302318 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/49228 About Tivic Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic's patented technology platform leverages stimulation on the trigeminal, sympathetic, an

Tivic Health® Systems, Inc. (("Tivic", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the second quarter of 2023 ended June 30, 2023 ("Q2 2023"). Second Quarter 2023 Financial Summary Gross profit of 37.5% in the second quarter of 2023, compared to 23.4% in the second quarter of 2022, on total revenue of $60 thousand in the second quarter of 2023 from $123 thousand in the second quarter of 2022. Net loss of $2.1 million in the second quarter of 2023, compared with $3.0 million in the second quarter of 2022. Cash and cash equivalents totaled $2.7 million as of the quarter end. Second Quarter 2023

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the first quarter of 2023 via pre-recorded conference call and webcast on Monday, August 14th, 2023 at 1:30 pm PT / 4:30 pm ET. Teleconference Details: Toll-Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 679005 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/48652 Shareholders also may submit questions in advance of the earnings call by sending them to the following email address - [email protected]. The deadline for submitting questions in advance of the

Gross Profit Increase by 61.3%; extends innovation pipeline to include vagus nerve stimulation. Tivic Health® Systems, Inc. (("Tivic", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce its financial results for the first quarter of 2023 ended March 31, 2023 ("Q1 2023"). First Quarter 2023 Financial Summary Gross profit increased 61.3% to $113 thousand in the first quarter of 2023, compared with $70 thousand in the first quarter of 2022, on a decrease of 12% in total revenue to $376 thousand in the first quarter 2023 from $428 thousand in first quarter 2022. Net loss of $2.1 million in the first quarter of 2023, comp

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the first quarter 2023 via a pre-recorded conference call and webcast on Monday, May 15th, 2023 at 1:30 pm PT / 4:30 pm ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 888610 Webcast Link https://www.webcaster4.com/Webcast/Page/2865/48259 Shareholders also may submit questions in advance of the earnings call by sending them to the following email address - [email protected]. The deadline for submitting questions in advance of the webc

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2022. Year over Year Highlights 46% growth in revenue 114% growth in direct to consumer channels 9X improvement in gross margin Jennifer Ernst, CEO of Tivic Health, commented, "We executed our 2022 strategy of increasing our direct-to-consumer sales, reducing the overall manufacturing costs of ClearUP, and seeding our product pipeline. However, supply chain shortages, market volatility and economic uncertainty left us, along with others, with challenges

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that the first study subject has been enrolled in the optimization study for Tivic Health's patent pending, non-invasive vagus nerve stimulation device. The study, being run by The Feinstein Institute of Bioelectronic Medicine, will identify device parameters, including frequency and duration of treatment, that optimally influence autonomic nervous system (ANS) function. The results will be used to inform clinical indication priority and commercial development. Enrollment is expected to be complete by early December. "The effectiveness of Tivic's non-inva

- Presentation will highlight Tivic Health's recent advancements in vagus nerve stimulation - Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that CEO Jennifer Ernst will presenting at the upcoming BioFuture 2024 Conference in New York, October 28-30. Ms. Ernst's presentation, Tuesday, October 29 at 2:30 p.m. EDT, will focus on the company's advances in bioelectronic medicine, including its recently released data on a new approach to vagus nerve stimulation. "This year, BioFuture 2024 has a strong focus on bioelectronic medicine, with industry leaders taking the stage," highlighted Jennifer Ernst, CEO

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it has received approval from The Feinstein Institutes' Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus nerve stimulation ("ncVNS") approach. This clinical research collaboration with Feinstein is designed to advance the development of Tivic Health's ncVNS technology by refining and optimizing stimulation parameters. Physiological measurements will be used to enhance device performance and refine specifications such as electrode positioning and electrical waveform parameters. The dat

Partners with leading growth strategy firm, Fletcher Spaght Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it has partnered with Fletcher Spaght ("FSI"), a leading healthcare growth strategy firm, to accelerate development of its commercial strategy for non-invasive cervical vagus nerve stimulation ("ncVNS"). Polaris Market Research estimates the global vagus nerve stimulation market will grow from $8.59 billion in 2021 to $21.3 billion in 2030, a 10.6% CAGR over the forecast period. Additionally, IDTechEx has forecast peripheral nerve stimulation, the segment targeted by Tivic Heal

Kimberly Bambach, Ms. Wolf's predecessor, continues with Tivic as advisor focused on strategic transactions and special projects Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions and other special projects. "Lisa has served as a senior member of Tivic's finance team for over two

Tivic Health® Systems, Inc. (("Tivic", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its second quarter 2024 financial results and discussed growth strategies based on its investments in vagus nerve stimulation ("VNS"). "This quarter is the start of a potentially transformational period for Tivic. We announced the results of our successful Phase 1 trial of a new approach to non-invasive vagus nerve stimulation. We are partnering with The Feinstein Institute of Bioelectronic Medicine for optimization, and we are continuing to build our intellectual property portfolio in an area of significant potential value to the company and

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q2 2024 financial results and a corporate update via pre-recorded conference call and webcast on Wednesday, August 14 at 1:30 PM PT / 4:30 PM ET. Current shareholders, interested individuals and future investors are encouraged to join the webcast to hear the company executives provide a corporate update that will highlight the importance of Tivic's vagus nerve research program and its market potential. The company invites questions to be submitted to [email protected] by August 11, 2024. Teleconference Details:

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the Virtual Annual General Meeting of Shareholders will be held on Friday, August 9, 2024 at 10:00 a.m., Pacific Time. The Company has adopted a virtual format for our Annual Meeting to provide a healthy, consistent, and convenient experience for all stockholders regardless of location.       WHEN: Friday, August 9, 2024       TIME: 10:00 AM Pacific Time       WHERE: www.virtualshareholdermeeting.com/TIVC2024 Only stockholders of record at the close of business on June 17, 2024 are entitled to

Three New Patents Granted in the US and Europe Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has received patent grants from the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO): US Patent 12,011,592 and European Patent EP3615133, both titled "Adaptive Trigger For a Microcurrent Stimulation Device", protect device and methods that the company uses to identify preferred treatment points and trigger a treatment mode. Triggers can be programmed in various ways to improve device performance and ease of use. European Patent EP3615134 e

Wall Street Capital Markets Veteran and Recognized All-Star Bio-Medical Technology Analyst joins Tivic Health's Governance Team Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to welcome Christina Valauri to its board of directors, effective July 1, 2024. Ms. Valauri has served as a strategic advisor to the company since April 2023, and brings over 30-years of experience as a seasoned capital markets professional with extensive analytical and management experience. Ms. Valauri has a proven track record as a senior healthcare analyst, US and Global Head of Equity Research, senior broker-

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

3 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

3 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

Shares of Indivior PLC (NASDAQ:INDV) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program. Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million. Indivior shares jumped 14.5% to $12.46 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Psyence Biomedical Ltd. (NASDAQ:PBM) rose 157.4% to $1.00 in pre-market trading after the company

US Patent 12,011,592 and European Patent EP3615133, both titled "Adaptive Trigger For a Microcurrent Stimulation Device", protect device and methods that the company uses to identify preferred treatment points and trigger a treatment mode. Triggers can be programmed in various ways to improve device performance and ease of use.European Patent EP3615134 entitled "Sinus Treatment Device With Adaptive Circuit" protects the device and methods that the company uses to dynamically adjust the stimulation voltage that is applied during a treatment phase, allowing for dynamic personalization of treatment. The dynamic changes in stimulation help to maximize comfort, enhance device performance, and enr

Gainers OneMedNet (NASDAQ:ONMD) stock moved upwards by 15.6% to $1.7 during Thursday's after-market session. The company's market cap stands at $40.5 million. 23andMe Holding (NASDAQ:ME) shares increased by 11.85% to $0.57. The company's market cap stands at $275.2 million. As per the news, the Q4 earnings report came out today. Biora Therapeutics (NASDAQ:BIOR) stock moved upwards by 10.0% to $0.55. The market value of their outstanding shares is at $19.7 million. Cue Health (NASDAQ:HLTH) shares moved upwards by 9.54% to $0.1. The company's market cap stands at $16.4 million. Accelerate Diagnostics (NASDAQ:AXDX) shares increased by 9.01% to $1.39. The market value of their outstanding s

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation ("ncVNS"). The company has entered into a collaboration agreement with The Feinstein Institutes for Medical Research at Northwell Health to optimize its ncVNS device therapy for use in specific clinical indications.Tivic Health will conduct a second 20-person clinical trial in collaboration with Theodoros Zanos, Ph.D., Associate Professor in the Institute of Bioelectronic Medicine and Head of the Neural and Data Science

U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping over 200 points on Thursday. The Dow traded up 0.63% to 39,300.69 while the NASDAQ rose 0.18% to 16,331.58. The S&P 500 also rose, gaining, 0.32% to 5,204.48       . Check This Out: Roblox, Beyond Meat And 3 Stocks To Watch Heading Into Thursday Leading and Lagging SectorsReal estate shares rose by 2% on Thursday. In trading on Thursday, information technology shares fell by 0.3%. Top Headline Roblox Corp (NYSE:RBLX) posted better-than-expected first-quarter financial results, but issued weak guidance. Roblox reported fiscal first-quarter 2024 bookings growth of 19% year-on-year to $92

Shares of Duolingo, Inc. (NASDAQ:DUOL) fell sharply during Thursday's session after the company reported first quarter financial results. Duolingo reported quarterly earnings of 57 cents per share which beat the analyst consensus estimate of 27 cents by 111.11%. Quarterly sales came in at $167.6 million which beat the analyst consensus estimate of $165.677 million and is a 44.91% increase from the same period last year, according to data from Benzinga Pro. Duolingo sees second-quarter revenues of between $175 million and $177.5 million, versus the $176.9 million estimate and full-year 2024 revenues of between $726.5 million and $735.5 million, versus the $728.23 million estimate. Du

Gainers Embecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday's regular session. The company's market cap stands at $814.1 million. As per the press release, Q2 earnings came out today. Seres Therapeutics (NASDAQ:MCRB) shares moved upwards by 36.28% to $1.02. The market value of their outstanding shares is at $154.2 million. The company's, Q1 earnings came out yesterday. G1 Therapeutics (NASDAQ:GTHX) shares rose 35.08% to $5.79. The company's market cap stands at $302.9 million. Vaccinex (NASDAQ:VCNX) shares rose 31.75% to $7.51. The market value of their outstanding shares is at $11.8 million. Zai Lab (NASDAQ:ZLAB) stock increased by 25.28% to $20.76. The company's

Tivic Health Systems Inc (NASDAQ:TIVC) shares are trading lower by 61% to $0.52 during Thursday’s session after the company disclosed the pricing of its public offering. The offering includes 4.710 million shares of common stock, along with Series A and Series B warrants to purchase additional shares. Each share and accompanying warrants are priced at $0.85. The Series A warrants are exercisable immediately and expire in one year, while the Series B warrants expire in five years. Maxim Group LLC is the sole placement agent for the offering. The company anticipates gross proceeds of approximately $4 million, pending customary closing conditions, with the closing expected around May 13.

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Thursday. The Dow traded up 0.48% to 39,244.53 while the NASDAQ rose 0.32% to 16,354.20. The S&P 500 also rose, gaining, 0.37% to 5,206.94       . Check This Out: Roblox, Beyond Meat And 3 Stocks To Watch Heading Into Thursday Leading and Lagging SectorsReal estate shares rose by 1.7% on Thursday. In trading on Thursday, information technology shares fell by 0.2%. Top Headline US Foods Holding Corp (NYSE:USFD) posted better-than-expected first-quarter financial results on Thursday. US Foods reported first-quarter FY24 sales growth of 4.8% year-on-year to $8.95 billion,